Related references
Note: Only part of the references are listed.Building on the success of anti-vascular endothelial growth factor therapy: a vision for the next decade
Anthony P. Adamis et al.
EYE (2020)
Predictive models of long-term anatomic outcome in age-related macular degeneration treated with as-needed Ranibizumab
Lucia Gonzalez-Buendia et al.
BMC OPHTHALMOLOGY (2017)
Predictors of Response to Intravitreal Anti-Vascular Endothelial Growth Factor Treatment of Age-Related Macular Degeneration
Anjali R. Shah et al.
AMERICAN JOURNAL OF OPHTHALMOLOGY (2016)
\Mechanisms of age-related macular degeneration and therapeutic opportunities
Menno van Lookeren Campagne et al.
JOURNAL OF PATHOLOGY (2014)
Twenty-four-Month Efficacy and Safety of 0.5 mg or 2.0 mg Ranibizumab in Patients with Subfoveal Neovascular Age-Related Macular Degeneration
Allen C. Ho et al.
OPHTHALMOLOGY (2014)
FIBROVASCULAR PIGMENT EPITHELIAL DETACHMENT IS A RISK FACTOR FOR LONG-TERM VISUAL DECAY IN NEOVASCULAR AGE-RELATED MACULAR DEGENERETION
Robert Hoerster et al.
RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES (2014)
Progression of Lesion Size in Untreated Eyes With Exudative Age-Related Macular Degeneration A Meta-analysis Using Lineweaver-Burk Plots
Tin Yan A. Liu et al.
JAMA OPHTHALMOLOGY (2013)
Causes of vision loss worldwide, 1990-2010: a systematic analysis
Rupert R. A. Bourne et al.
LANCET GLOBAL HEALTH (2013)
Adhesion Failures Determine the Pattern of Choroidal Neovascularization in the Eye: A Computer Simulation Study
Abbas Shirinifard et al.
PLOS COMPUTATIONAL BIOLOGY (2012)
The correlation structure of longitudinal measurements of vision in patients with macular degeneration
Tomasz Burzykowski et al.
PHARMACEUTICAL STATISTICS (2011)
The Effects of a Flexible Visual Acuity-Driven Ranibizumab Treatment Regimen in Age-Related Macular Degeneration: Outcomes of a Drug and Disease Model
Frank G. Holz et al.
INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE (2010)
Natural History of Predominantly Classic, Minimally Classic, and Occult Subgroups in Exudative Age-related Macular Degeneration
Ankoor R. Shah et al.
OPHTHALMOLOGY (2009)
Randomized, double-masked, sham-controlled trial of ranibizumab for neovascular age-related macular degeneration: PIER study year 1
Carl D. Regillo et al.
AMERICAN JOURNAL OF OPHTHALMOLOGY (2008)
Modelling response time profiles in the absence of drug concentrations: Definition and performance evaluation of the K-PD model
P. Jacqmin et al.
JOURNAL OF PHARMACOKINETICS AND PHARMACODYNAMICS (2007)
Ranibizumab for neovascular age-related macular degeneration
Philip J. Rosenfeld et al.
NEW ENGLAND JOURNAL OF MEDICINE (2006)
Ranibizumab versus verteporfin for neovascular age-related macular degeneration
David M. Brown et al.
NEW ENGLAND JOURNAL OF MEDICINE (2006)
Share Paper
